NCT06620809View on ClinicalTrials.gov

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

PHASE1RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2027

Conditions
Neuromyelitis Optica Spectrum Disorders
Interventions
DRUG

Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection

Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection（5×10\^9 particles）

DRUG

A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection

Extracellular vesicles placebo(5×10\^9 particles）

Trial Locations (1)

430000

RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

iRegene Therapeutics Co., Ltd.

INDUSTRY

lead

Tongji Hospital

OTHER